logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Q

Quchang Ouyang

hunan cancer hospital
H指数:23
被引数:2,536

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Benmelstobart plus antiangiogenic therapy vs chemotherapy for metastatic triple-negative breast cancer: phase III trial

贝姆勒斯特巴特联合抗血管生成疗法与化疗治疗转移性三阴性乳腺癌：III期试验

npj Breast Cancer
IF7.6
2026-09-040
OA
Jiayu Wang; Quchang Oyang; Zhihong Wang; Qingyuan Zhang; Yu Ren; Jincai Zhong; Tao Sun; Zhongsheng Tong; Wenxian Zhou; Xiaojia Wang; Yahua Zhong; Xiaohua Zeng; Yuee Teng; Jing Sun; Yunhong Xia; Cuizhi Geng; Fuming Qiu; Lu Gan; Huadong Zhao; Ning Liao; Hongyan Ying; Xiaoyan Li; Xunqiang Wang; Binghe Xu
Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial

Disitamab vedotin用于HER2阳性肝转移性乳腺癌：RC48-C006 II/III期试验的III期结果

Nature Communications
IF15.7
2026-08-270
OAAI
Jiayu Wang; Quchang Ouyang; Weimin Xie; Zhaofeng Niu; Qingyuan Zhang; Xi Yan; Yue’e Teng; Jianying Chang; Ying Cheng; Airong Wang; Jingfen Wang; Herui Yao; Zhuangqing Yang; Tao Sun; Zhongsheng Tong; Xinhong Wu; Yongsheng Wang; Enxiang Zhou; Xiangshun Kong; Xujuan Wang; De Zeng; Shanshan Gu; Yanyan Hou; Dandan Gao; Zerui Qu; Chenran Han; Jianmin Fang; Binghe Xu
First-in-Human Study of the PARP Inhibitor HWH340 in Advanced Solid Tumors with Enrichment for Homologous Recombination Repair Gene Mutations

HWH340 PARP抑制剂在富集同源重组修复基因突变的晚期实体瘤中的首次人体研究

Drug Design Development and Therapy
IF5.1
2026-01-010
OAAI
Zhang, Jie; Wang, Xiaojia; Xu, Huiting; Zang, Aimin; Zhao, Jun; Chen, Jinping; Lei, Ruiwen; Zhang, Zhen; Hao, Chunfang; Liu, Yunpeng; Zhou, Rongwei; He, Lijia; Sun, Tao; Ouyang, Quchang; Chen, Sheng; Xu, Jingqiao; Zhou, Wei; Shi, Yehui; Tong, Zhongsheng
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial

新型CDK2/4/6抑制剂culmerciclib (TQB3616) 联合氟维司群治疗HR阳性HER2-negative晚期乳腺癌: 一项随机、双盲、3期临床试验

Signal Transduction and Targeted Therapy
IF52.7
2025-12-180
OAAI
Yongmei Yin; Qingyuan Zhang; Tao Sun; Chunfang Hao; Zhihong Wang; Jin Yang; Yongsheng Wang; Yanxia Shi; Jing Sun; Quchang Ouyang; Haichuan Su; Jinsheng Wu; Lu Gan; Meng Han; Liming Gao; Xiaojia Wang; Bing Zhao; Hui Li; Jiuda Zhao; Hongwei Yang; Fangling Ning; Fuguo Tian; Juliang Zhang; Hongmei Sun; Zhaofeng Niu; Hong Zong; Aimin Zang; Xinshuai Wang; Xinyu Qian; Shikai Wu; Jianyun Nie; Lijia He; Ying Cheng; Yanrong Hao; Yi Zhai; Huiping Li; Jingfen Wang; Shihong Wei; Man Li; Yunjiang Liu; Hongqiang Guo; Qun Hu; Lina Liu; Xinghua Han; Ruizhen Luo; Mingli Ni; Xianjun Tang; Zhenhua Zhai; Meiqian Ding; Haibo Wang; Peng Shen; Xian Wang; Lian Liu; Wenyan Chen; Gang Liu; Zhengwen Cai; Zefei Jiang
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial

fruroliparib 联合或不联合 apatinib 治疗 HER2 阴性转移性乳腺癌携带胚系 BRCA1/2 突变患者（FABULOUS）：一项多中心、三臂、开放标签、随机、III 期试验的期中分析

The Lancet Oncology
IF0
2025-11-240
PRE
Huiping Li; Jieqiong Liu; Quchang Ouyang; Shusen Wang; Yaxin Liu; Yuee Teng; Xiaojia Wang; Jing Cheng; Zhongsheng Tong; Tao Sun; Min Yan; Xin Zhou; Fanfan Li; Jianyun Nie; Zhi-Ming Shao; Changsheng Ye; Yongsheng Wang; Xiaohong Wu; Zhihua Li; Yudong Wu
Real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab

基于inetetamab疗法的真实世界有效性与安全性：在曾接受曲妥珠单抗治疗的HER2阳性转移性乳腺癌患者中的研究

Frontiers in Oncology
IF3.3
2025-09-020
OA
Yangyang Duan; Tao Sun; Zhanhong Chen; Quchang Ouyang; Kai Li; Min Yan; Zheng Lv; Zhaohui Li; Li Man; Xu Luo; Yuyang Dong; Mingxi Jing; Yan Wang; Xiangyu Guo; Junnan Xu; Xiaorui Li; Cui Jiang; Ying E; Lei Jiang; Hui Cao; Yufeng Jia; Jie Wu; Huan Li; Liang Zhang; Yujun Jiang; Zhichao Gao; Fangyuan Dong
BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+/HER2- advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study

BEBT-209，一种主要CDK4选择性抑制剂，用于治疗HR+/HER2-晚期乳腺癌（BECTOP1）：一项1期、多中心、开放标签研究

breast
IF0
2025-07-190
PREAI
Zhe-Yu Hu; Kegang Jiang; Can Tian; Fan Zhang; Yehui Shi; Ying Wang; Wei Li; Biao Wu; Boni Ding; Liping Liu; Huawu Xiao; Xiaohong Yang; Jing Li; Ning Xie; Binliang Liu; Shouman Wang; Quchang Ouyang
Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial

KN026和多西他赛治疗HER2阳性乳腺癌的疗效与安全性：一项II期临床试验

CANCER COMMUNICATIONS
IF24.9
2025-01-181
OAAI
Ma, Jianli; Wang, Jingxuan; Xu, Ting; Ouyang, Quchang; Wang, Xiaojia; Wang, Jingfen; Gan, Lu; Ouyang, Zhong; Lin, Daren; Sun, Tao; Shan, Changping; Yao, Herui; Zhang, Baochun; Li, Zhengguang; Zhuang, Zhixiang; Lu, Ying; Yang, Hongwei; Huang, Jian; Yang, Xingwang; Sun, Hongmei; Zhang, Qingyuan
Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2-, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE study

Abemaciclib联合内分泌治疗作为激素受体阳性，HER2-高危早期乳腺癌的辅助治疗: III期随机monarchE研究的5年中国人群分析

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2024-10-230
OAAI
Zhang, Qingyuan; Shen, Kunwei; Song, Chuan-gui; Ouyang, Quchang; Liu, Zhenzhen; Liu, Qiang; Feng, Jifeng; Chiu, Joanne W. Y.; Tang, Jinhai; Jiang, Zefei; Tseng, Ling-Ming; Wang, Xiaojia; Yang, Liu; Qian, Chenxi; Shao, Zhimin
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial

Pyrotinib与安慰剂联合曲妥珠单抗和多西他赛作为HER2阳性转移性乳腺癌患者的一线治疗 (PHILA): 随机，双盲，多中心，3期试验

BMJ-BRITISH MEDICAL JOURNAL
IF42.7
2023-10-3134
OAAI
Ma, Fei; Yan, Min; Li, Wei; Ouyang, Quchang; Tong, Zhongsheng; Teng, Yuee; Wang, Yongsheng; Wang, Shusen; Geng, Cuizhi; Luo, Ting; Zhong, Jincai; Zhang, Qingyuan; Liu, Qiang; Zeng, Xiaohua; Sun, Tao; Mo, Qinguo; Liu, Hu; Cheng, Ying; Cheng, Jing; Wang, Xiaojia; Nie, Jianyun; Yang, Jin; Wu, Xinhong; Wang, Xinshuai; Li, Huiping; Ye, Changsheng; Dong, Fangli; Wu, Shuchao; Zhu, Xiaoyu; Xu, Binghe
Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial

Pyrotinib联合来曲唑治疗激素受体阳性、人表皮生长因子受体2阳性转移性乳腺癌 (PLEHERM): 一项多中心、单臂、II期临床试验

BMC MEDICINE
IF8.3
2023-06-266
OAAI
Hu, Zhe-Yu; Yan, Min; Xiong, Huihua; Ran, Li; Zhong, Jincai; Luo, Ting; Sun, Tao; Xie, Ning; Liu, Liping; Yang, Xiaohong; Xiao, Huawu; Li, Jing; Liu, Binliang; Ouyang, Quchang
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study

Pamiparib在具有生殖系BRCA突变的局部晚期或转移性HER2-negative乳腺癌患者中的应用: 一项II期研究

BREAST CANCER RESEARCH AND TREATMENT
IF3
2022-12-0212
OAAI
Xu, Binghe; Sun, Tao; Shi, Yanxia; Cui, Jiuwei; Yin, Yongmei; Ouyang, Quchang; Liu, Qiang; Zhang, Qingyuan; Chen, Yiding; Wang, Shouman; Wang, Xiaojia; Tong, Zhongsheng; Zhong, Yahua; Wang, Jiayu; Yan, Min; Yan, Xi; Wang, Chuan; Feng, Jifeng; Wang, Xiuli; Hu, Gang; Cheng, Ying; Ge, Ruimin; Zhu, Zhaoyin; Zhang, Wa; Shao, Zhimin
A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2022-10-241
OAAI
Yan, Min; Yuan, Peng; Ouyang, Quchang; Cheng, Ying; Han, Guohui; Wang, Dewei; Ran, Li; Sun, Tao; Zhao, Da; Bai, Yuju; Yang, Shun'e; Wang, Xiaojia; Wu, Rong; Zeng, Xiaohua; Yao, Herui; Ji, Xuening; Jiang, Jun; Hu, Xiaohua; Lin, Haifeng; Zheng, Liping; Zhu, Zhitu; Ge, Wei; Yang, Junlan; Cui, Tongjian; Zhang, Xiaozhi; Lu, Fangyang; Li, Wenhui; Xu, Hongyan; Kang, Mafei; Gong, Ping; Zou, Liqun; Liu, Jiang; Zhang, Hongliang; Yu, Hao; Xu, Binghe

研究方向

暂未获取到该数据
N
Ning Xie
H 指数:41论文数:426被引数:6,335
徐兵河 封面图
徐兵河
H 指数:63论文数:785被引数:2.8万
X
Xiaojia Wang
H 指数:34论文数:288被引数:8,179
C
Can Tian
H 指数:8论文数:37被引数:267
Z
Zhe-Yu Hu
H 指数:18论文数:69被引数:1,119
M
Min Yan
H 指数:68论文数:759被引数:1.9万
Z
Zhongsheng Tong
H 指数:31论文数:220被引数:4,919
孙涛 封面图
孙涛
H 指数:28论文数:181被引数:3,804
孙涛 封面图
孙涛
H 指数:43论文数:353被引数:1.1万
Y
Yuee Teng
H 指数:31论文数:144被引数:2,696